Evidence map›Paper›PMID 31407495›Full record

ArticleCancer medicine2019

Prognostic significance of laterality in renal cell carcinoma: A population-based study from the surveillance, epidemiology, and end results (SEER) database.

Shengjie Guo, Kai Yao, Xiaobo He, Shulin Wu, Yunlin Ye, Junxing Chen, Chin-Lee Wu

Abstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shengjie GuoDepartment of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.ORCID https://orcid.org/0000-0001-7953-8775
Kai YaoDepartment of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Xiaobo HeDepartment of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Shulin WuDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Yunlin YeDepartment of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.ORCID https://orcid.org/0000-0001-5424-7066
Junxing ChenDepartment of Urology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Chin-Lee WuDepartment of Urology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-0444-0068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVarious prognostic characteristics have been established in the renal cell carcinoma (RCC). However, the impact of tumor laterality is unknown. The objective of the current study was to explore the predictive and prognostic impact of tumor laterality of RCC after surgery.

methodsThis investigation was a population-based retrospective cohort study of patients with RCC from the surveillance, epidemiology, and end results (SEER) database in the USA. All patients received surgical treatment between January 2010 and December 2014. Cancer-specific survival (CSS) measured from the time of surgery.

resultsThis study identified 41 138 surgically treated RCC patients: Of these patients, 50.6% had right-sided RCC, 59.5% were younger than 65 years of age, 63.8% were male, and 81.0% were Caucasian. The stage distribution was 67.0% (I), 9.5% (II), 17.1% (III), and 6.4% (IV). Patients with right-sided RCC were more likely to have favorable clinicopathological features compared with patients with left-sided RCC. In adjusted analyses, patients with right-sided RCC showed significantly better CSS than those with left-sided RCC within different subgroups including tumor size ≥10 cm (P = .004), age <65 years (P = .002), male gender (P = .001), Caucasian race (P = .001), clear cell carcinoma type (P = .024), and radical nephrectomy (P = 0.008). Moreover, in the subgroup of tumor size ≥10 cm, right-sided cancer was an independent predictor of CSS (P = .022).

conclusionRight-sided RCC is associated with more early-stage, low-grade disease and shows better CSS than left-sided RCC. Moreover, laterality remained as an independent prognostic factor for cancer-specific survival in subgroup of tumor size ≥10 cm RCC.

Indexed as

Carcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleNeoplasm StagingPrognosisRetrospective StudiesRisk FactorsSEER ProgramSurvival AnalysisTreatment OutcomeUnited Stateslateralitynephrectomyprognosisrenal cell carcinomaSEER

Identifiers

PMID31407495
PMCPMC6745836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.